Topic: Research News
Researchers from Northwestern Medicine found that a new test called apolipoprotein B (apoB) is better than current tests for predicting who needs more aggressive treatment to reduce the risk of heart attacks and strokes. The study, published in JAMA, used a computer simulation to compare three approaches for guiding treatment: using apoB, LDL cholesterol, or non-HDL cholesterol levels.
Millions of Americans have a blood test every year to measure LDL, often called
Implications
Researchers from Northwestern Medicine found that a new test called apolipoprotein B (apoB) is better than current tests for predicting who needs more aggressive treatment to reduce the risk of heart attacks and strokes. The study, published in JAMA, used a computer simulation to compare three approaches for guiding treatment: using apoB, LDL cholesterol, or non-HDL cholesterol levels.
Source: https://www.sciencedaily.com/releases/2026/06/260626125714.htm
Journal Reference:
- Samuel Luebbe, Allan D. Sniderman, Andrew E. Moran, John T. Wilkins, Ciaran N. Kohli-Lynch. Cost-Effectiveness of ApoB, Non–HDL-C, and LDL-C Goals for Primary Prevention Lipid-Lowering Therapy. JAMA, 2026; 335 (17): 1507 DOI: 10.1001/jama.2026.2986
.
Leave a Comment